Table 1.
Primary study endpoints following different anti-HER2 therapies in BT474 cell line-derived and BCM-3963 patient-derived xenograft models.
| Model/treatment | No. of mice | Median TTP days (95% CI) | Median TTR days (95% CI) | Median TCR days (95% CI) | CR (%) |
|---|---|---|---|---|---|
| BT474-AZ model | |||||
| E2 + Vehicle | 9 | 8 (4.58–35.36) | – | – | 0 |
| ED + Vehicle | 10 | 25 (5.85–42.2) | – | – | 0 |
| ED + N | 13 | – | 2 (1.68–2.43) | 14 (14.00–31.00) | 100 |
| ED + T | 12 | – | 5 (2.64–6.44) | 19 (10.00–28.00) | 100 |
| ED + P | 12 | – | 18 (6.93–49.01) | 54 (24.00–NA) | 92 |
| ED + N + T | 13 | – | 2 (1.29–1.95) | 10 (7.00–14.00) | 100 |
| ED + P + T | 14 | – | 4 (2.54–5.51) | 14 (14.00–31.00) | 100 |
| BCM-3963 model | |||||
| Vehicle | 15 | 11 (7.57–17.29) | – | – | 0 |
| N | 15 | – | 4 (2.52–7.10) | 17 (14.00–28.00) | 100 |
| T | 14 | 16 (6.52–22.59) | – | – | 0 |
| P | 13 | 19 (10.89–25.29) | – | – | 0 |
| N + T | 19 | – | 6 (3.22–8.31) | 14 (14.00–17.00) | 100 |
| P + T | 16 | 17 (13.61–22.14) | – | – | 0 |
E2 estrogen, ED estrogen deprivation, N neratinib, T trastuzumab, P pertuzumab, TTP time to tumor progression, TTR time to tumor regression, TCR time to complete response, CR complete response, CI confidence interval.